Using Patient-Level Data to Develop Meaningful Cross-Trial Comparisons of Visual Impairment in Individuals with Diabetic Macular Edema.
Identifieur interne : 001F72 ( PubMed/Curation ); précédent : 001F71; suivant : 001F73Using Patient-Level Data to Develop Meaningful Cross-Trial Comparisons of Visual Impairment in Individuals with Diabetic Macular Edema.
Auteurs : Sobha Sivaprasad [Royaume-Uni] ; Stephane A. Regnier [Suisse] ; Franck Fajnkuchen [France] ; Jonathan Wright [Royaume-Uni] ; Alan R. Berger [Canada] ; Paul Mitchell [Australie] ; Michael Larsen [Danemark]Source :
- Advances in therapy [ 1865-8652 ] ; 2016.
Descripteurs français
- KwdFr :
- Acuité visuelle, Adulte d'âge moyen, Facteur de croissance endothéliale vasculaire de type A (antagonistes et inhibiteurs), Femelle, Humains, Inhibiteurs de l'angiogenèse (usage thérapeutique), Injections intravitréennes, Modèles statistiques, Mâle, Oedème maculaire (diagnostic), Oedème maculaire (traitement médicamenteux), Oedème maculaire (étiologie), Protéines de fusion recombinantes (usage thérapeutique), Ranibizumab (usage thérapeutique), Récepteurs aux facteurs de croissance endothéliale vasculaire (usage thérapeutique), Rétinopathie diabétique (), Rétinopathie diabétique (anatomopathologie), Sujet âgé, Sélection de patients, Thérapie laser (), Troubles de la vision (diagnostic), Troubles de la vision (étiologie), Évaluation des résultats des patients.
- MESH :
- anatomopathologie : Rétinopathie diabétique.
- antagonistes et inhibiteurs : Facteur de croissance endothéliale vasculaire de type A.
- diagnostic : Oedème maculaire, Troubles de la vision.
- traitement médicamenteux : Oedème maculaire.
- usage thérapeutique : Inhibiteurs de l'angiogenèse, Protéines de fusion recombinantes, Ranibizumab, Récepteurs aux facteurs de croissance endothéliale vasculaire.
- étiologie : Oedème maculaire, Troubles de la vision.
- Acuité visuelle, Adulte d'âge moyen, Femelle, Humains, Injections intravitréennes, Modèles statistiques, Mâle, Rétinopathie diabétique, Sujet âgé, Sélection de patients, Thérapie laser, Évaluation des résultats des patients.
English descriptors
- KwdEn :
- Aged, Angiogenesis Inhibitors (therapeutic use), Diabetic Retinopathy (complications), Diabetic Retinopathy (pathology), Female, Humans, Intravitreal Injections, Laser Therapy (methods), Macular Edema (diagnosis), Macular Edema (drug therapy), Macular Edema (etiology), Male, Middle Aged, Models, Statistical, Patient Outcome Assessment, Patient Selection, Ranibizumab (therapeutic use), Receptors, Vascular Endothelial Growth Factor (therapeutic use), Recombinant Fusion Proteins (therapeutic use), Vascular Endothelial Growth Factor A (antagonists & inhibitors), Vision Disorders (diagnosis), Vision Disorders (etiology), Visual Acuity.
- MESH :
- chemical , antagonists & inhibitors : Vascular Endothelial Growth Factor A.
- chemical , therapeutic use : Angiogenesis Inhibitors, Ranibizumab, Receptors, Vascular Endothelial Growth Factor, Recombinant Fusion Proteins.
- complications : Diabetic Retinopathy.
- diagnosis : Macular Edema, Vision Disorders.
- drug therapy : Macular Edema.
- etiology : Macular Edema, Vision Disorders.
- methods : Laser Therapy.
- pathology : Diabetic Retinopathy.
- Aged, Female, Humans, Intravitreal Injections, Male, Middle Aged, Models, Statistical, Patient Outcome Assessment, Patient Selection, Visual Acuity.
Abstract
The aim of this study was to assess the impact of baseline characteristics on visual outcome of patients with diabetic macular edema and compare the results of clinical trials with different patient populations.
DOI: 10.1007/s12325-016-0310-0
PubMed: 26951552
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001F97
Links to Exploration step
pubmed:26951552Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Using Patient-Level Data to Develop Meaningful Cross-Trial Comparisons of Visual Impairment in Individuals with Diabetic Macular Edema.</title><author><name sortKey="Sivaprasad, Sobha" sort="Sivaprasad, Sobha" uniqKey="Sivaprasad S" first="Sobha" last="Sivaprasad">Sobha Sivaprasad</name><affiliation wicri:level="1"><nlm:affiliation>NIHR Biomedical Research Centre, Moorfields Eye Hospital, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>NIHR Biomedical Research Centre, Moorfields Eye Hospital, London</wicri:regionArea></affiliation></author><author><name sortKey="Regnier, Stephane A" sort="Regnier, Stephane A" uniqKey="Regnier S" first="Stephane A" last="Regnier">Stephane A. Regnier</name><affiliation wicri:level="1"><nlm:affiliation>Novartis Pharma AG, Basel, Switzerland. stephane.regnier@novartis.com.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Novartis Pharma AG, Basel</wicri:regionArea></affiliation></author><author><name sortKey="Fajnkuchen, Franck" sort="Fajnkuchen, Franck" uniqKey="Fajnkuchen F" first="Franck" last="Fajnkuchen">Franck Fajnkuchen</name><affiliation wicri:level="1"><nlm:affiliation>Centre Ophthalmologique d'Imagerie et de Laser, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Centre Ophthalmologique d'Imagerie et de Laser, Paris</wicri:regionArea></affiliation></author><author><name sortKey="Wright, Jonathan" sort="Wright, Jonathan" uniqKey="Wright J" first="Jonathan" last="Wright">Jonathan Wright</name><affiliation wicri:level="1"><nlm:affiliation>Numerus Ltd, Wokingham, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Numerus Ltd, Wokingham</wicri:regionArea></affiliation></author><author><name sortKey="Berger, Alan R" sort="Berger, Alan R" uniqKey="Berger A" first="Alan R" last="Berger">Alan R. Berger</name><affiliation wicri:level="1"><nlm:affiliation>St Michael's Hospital, Toronto, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>St Michael's Hospital, Toronto</wicri:regionArea></affiliation></author><author><name sortKey="Mitchell, Paul" sort="Mitchell, Paul" uniqKey="Mitchell P" first="Paul" last="Mitchell">Paul Mitchell</name><affiliation wicri:level="1"><nlm:affiliation>University of Sydney, Sydney, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>University of Sydney, Sydney</wicri:regionArea></affiliation></author><author><name sortKey="Larsen, Michael" sort="Larsen, Michael" uniqKey="Larsen M" first="Michael" last="Larsen">Michael Larsen</name><affiliation wicri:level="1"><nlm:affiliation>Department of Ophthalmology, Glostrup Hospital, University of Copenhagen, Glostrup, Denmark.</nlm:affiliation><country xml:lang="fr">Danemark</country><wicri:regionArea>Department of Ophthalmology, Glostrup Hospital, University of Copenhagen, Glostrup</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26951552</idno><idno type="pmid">26951552</idno><idno type="doi">10.1007/s12325-016-0310-0</idno><idno type="wicri:Area/PubMed/Corpus">001F97</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001F97</idno><idno type="wicri:Area/PubMed/Curation">001F72</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001F72</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Using Patient-Level Data to Develop Meaningful Cross-Trial Comparisons of Visual Impairment in Individuals with Diabetic Macular Edema.</title><author><name sortKey="Sivaprasad, Sobha" sort="Sivaprasad, Sobha" uniqKey="Sivaprasad S" first="Sobha" last="Sivaprasad">Sobha Sivaprasad</name><affiliation wicri:level="1"><nlm:affiliation>NIHR Biomedical Research Centre, Moorfields Eye Hospital, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>NIHR Biomedical Research Centre, Moorfields Eye Hospital, London</wicri:regionArea></affiliation></author><author><name sortKey="Regnier, Stephane A" sort="Regnier, Stephane A" uniqKey="Regnier S" first="Stephane A" last="Regnier">Stephane A. Regnier</name><affiliation wicri:level="1"><nlm:affiliation>Novartis Pharma AG, Basel, Switzerland. stephane.regnier@novartis.com.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Novartis Pharma AG, Basel</wicri:regionArea></affiliation></author><author><name sortKey="Fajnkuchen, Franck" sort="Fajnkuchen, Franck" uniqKey="Fajnkuchen F" first="Franck" last="Fajnkuchen">Franck Fajnkuchen</name><affiliation wicri:level="1"><nlm:affiliation>Centre Ophthalmologique d'Imagerie et de Laser, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Centre Ophthalmologique d'Imagerie et de Laser, Paris</wicri:regionArea></affiliation></author><author><name sortKey="Wright, Jonathan" sort="Wright, Jonathan" uniqKey="Wright J" first="Jonathan" last="Wright">Jonathan Wright</name><affiliation wicri:level="1"><nlm:affiliation>Numerus Ltd, Wokingham, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Numerus Ltd, Wokingham</wicri:regionArea></affiliation></author><author><name sortKey="Berger, Alan R" sort="Berger, Alan R" uniqKey="Berger A" first="Alan R" last="Berger">Alan R. Berger</name><affiliation wicri:level="1"><nlm:affiliation>St Michael's Hospital, Toronto, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>St Michael's Hospital, Toronto</wicri:regionArea></affiliation></author><author><name sortKey="Mitchell, Paul" sort="Mitchell, Paul" uniqKey="Mitchell P" first="Paul" last="Mitchell">Paul Mitchell</name><affiliation wicri:level="1"><nlm:affiliation>University of Sydney, Sydney, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>University of Sydney, Sydney</wicri:regionArea></affiliation></author><author><name sortKey="Larsen, Michael" sort="Larsen, Michael" uniqKey="Larsen M" first="Michael" last="Larsen">Michael Larsen</name><affiliation wicri:level="1"><nlm:affiliation>Department of Ophthalmology, Glostrup Hospital, University of Copenhagen, Glostrup, Denmark.</nlm:affiliation><country xml:lang="fr">Danemark</country><wicri:regionArea>Department of Ophthalmology, Glostrup Hospital, University of Copenhagen, Glostrup</wicri:regionArea></affiliation></author></analytic><series><title level="j">Advances in therapy</title><idno type="eISSN">1865-8652</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Angiogenesis Inhibitors (therapeutic use)</term><term>Diabetic Retinopathy (complications)</term><term>Diabetic Retinopathy (pathology)</term><term>Female</term><term>Humans</term><term>Intravitreal Injections</term><term>Laser Therapy (methods)</term><term>Macular Edema (diagnosis)</term><term>Macular Edema (drug therapy)</term><term>Macular Edema (etiology)</term><term>Male</term><term>Middle Aged</term><term>Models, Statistical</term><term>Patient Outcome Assessment</term><term>Patient Selection</term><term>Ranibizumab (therapeutic use)</term><term>Receptors, Vascular Endothelial Growth Factor (therapeutic use)</term><term>Recombinant Fusion Proteins (therapeutic use)</term><term>Vascular Endothelial Growth Factor A (antagonists & inhibitors)</term><term>Vision Disorders (diagnosis)</term><term>Vision Disorders (etiology)</term><term>Visual Acuity</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Acuité visuelle</term><term>Adulte d'âge moyen</term><term>Facteur de croissance endothéliale vasculaire de type A (antagonistes et inhibiteurs)</term><term>Femelle</term><term>Humains</term><term>Inhibiteurs de l'angiogenèse (usage thérapeutique)</term><term>Injections intravitréennes</term><term>Modèles statistiques</term><term>Mâle</term><term>Oedème maculaire (diagnostic)</term><term>Oedème maculaire (traitement médicamenteux)</term><term>Oedème maculaire (étiologie)</term><term>Protéines de fusion recombinantes (usage thérapeutique)</term><term>Ranibizumab (usage thérapeutique)</term><term>Récepteurs aux facteurs de croissance endothéliale vasculaire (usage thérapeutique)</term><term>Rétinopathie diabétique ()</term><term>Rétinopathie diabétique (anatomopathologie)</term><term>Sujet âgé</term><term>Sélection de patients</term><term>Thérapie laser ()</term><term>Troubles de la vision (diagnostic)</term><term>Troubles de la vision (étiologie)</term><term>Évaluation des résultats des patients</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Vascular Endothelial Growth Factor A</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Angiogenesis Inhibitors</term><term>Ranibizumab</term><term>Receptors, Vascular Endothelial Growth Factor</term><term>Recombinant Fusion Proteins</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Rétinopathie diabétique</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Facteur de croissance endothéliale vasculaire de type A</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Diabetic Retinopathy</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Macular Edema</term><term>Vision Disorders</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Oedème maculaire</term><term>Troubles de la vision</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Macular Edema</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Macular Edema</term><term>Vision Disorders</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Laser Therapy</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Diabetic Retinopathy</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Oedème maculaire</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Inhibiteurs de l'angiogenèse</term><term>Protéines de fusion recombinantes</term><term>Ranibizumab</term><term>Récepteurs aux facteurs de croissance endothéliale vasculaire</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Oedème maculaire</term><term>Troubles de la vision</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Humans</term><term>Intravitreal Injections</term><term>Male</term><term>Middle Aged</term><term>Models, Statistical</term><term>Patient Outcome Assessment</term><term>Patient Selection</term><term>Visual Acuity</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Acuité visuelle</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Humains</term><term>Injections intravitréennes</term><term>Modèles statistiques</term><term>Mâle</term><term>Rétinopathie diabétique</term><term>Sujet âgé</term><term>Sélection de patients</term><term>Thérapie laser</term><term>Évaluation des résultats des patients</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The aim of this study was to assess the impact of baseline characteristics on visual outcome of patients with diabetic macular edema and compare the results of clinical trials with different patient populations.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26951552</PMID><DateCreated><Year>2016</Year><Month>04</Month><Day>27</Day></DateCreated><DateCompleted><Year>2017</Year><Month>09</Month><Day>11</Day></DateCompleted><DateRevised><Year>2017</Year><Month>09</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1865-8652</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>4</Issue><PubDate><Year>2016</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Advances in therapy</Title><ISOAbbreviation>Adv Ther</ISOAbbreviation></Journal><ArticleTitle>Using Patient-Level Data to Develop Meaningful Cross-Trial Comparisons of Visual Impairment in Individuals with Diabetic Macular Edema.</ArticleTitle><Pagination><MedlinePgn>597-609</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12325-016-0310-0</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The aim of this study was to assess the impact of baseline characteristics on visual outcome of patients with diabetic macular edema and compare the results of clinical trials with different patient populations.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A model was created with patient-level data from the RESPOND/RESTORE trials to estimate the impact of baseline characteristics on increases in best-corrected visual acuity (BCVA) with anti-vascular endothelial growth factor therapies, measured by letters gained on the Early Treatment Diabetic Retinopathy Study scale from baseline to month 12. Mean BCVA gains with ranibizumab 0.5 mg pro re nata or laser photocoagulation monotherapy were predicted, assuming baseline characteristics equivalent to those in the VIVID-DME/VISTA-DME trials. These results were compared with the gain with aflibercept 2.0 mg every 8 weeks in VIVID-DME/VISTA-DME. Sensitivity analyses assessed outcome robustness.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Baseline BCVA and central retinal thickness differed significantly between trials. In unadjusted data, patients in RESPOND/RESTORE receiving ranibizumab gained an additional 6.6 letters [95% confidence interval (CI): 4.5-8.7] compared with patients receiving laser monotherapy. After adjusting data to assume baseline characteristics equivalent to VIVID-DME/VISTA-DME, patients receiving ranibizumab were predicted to gain an additional 9.9 letters (95% CI: 7.3-12.4) compared with those receiving laser monotherapy. These results were similar (0.1-letter difference in favor of aflibercept; 95% CI: -2.9 to 3.2; P = 0.94) to the gain in BCVA in patients receiving aflibercept in VIVID-DME/VISTA-DME compared with those receiving laser monotherapy (10.0 letters, 95% CI: 8.3-11.7).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">After adjusting for baseline characteristics, the difference in letters gained between patients receiving ranibizumab versus aflibercept was non-significant across trials, highlighting the importance of adjusting for baseline characteristics in future comparisons.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">Novartis Pharma AG.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sivaprasad</LastName><ForeName>Sobha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>NIHR Biomedical Research Centre, Moorfields Eye Hospital, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>King's College Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Regnier</LastName><ForeName>Stephane A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Novartis Pharma AG, Basel, Switzerland. stephane.regnier@novartis.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fajnkuchen</LastName><ForeName>Franck</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Centre Ophthalmologique d'Imagerie et de Laser, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hôpital Avicenne, Assistance Publique Hôpitaux de Paris, Bobigny, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wright</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Numerus Ltd, Wokingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berger</LastName><ForeName>Alan R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>St Michael's Hospital, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitchell</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>University of Sydney, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larsen</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Glostrup Hospital, University of Copenhagen, Glostrup, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Eye Clinic, Kennedy Center, Glostrup, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>03</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Adv Ther</MedlineTA><NlmUniqueID>8611864</NlmUniqueID><ISSNLinking>0741-238X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020533">Angiogenesis Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance></Chemical><Chemical><RegistryNumber>15C2VL427D</RegistryNumber><NameOfSubstance UI="C533178">aflibercept</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D040262">Receptors, Vascular Endothelial Growth Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>ZL1R02VT79</RegistryNumber><NameOfSubstance UI="D000069579">Ranibizumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>T</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Eye (Lond). 2012 Apr;26(4):485-93</RefSource><PMID Version="1">22241014</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMC Ophthalmol. 2015;15:52</RefSource><PMID Version="1">25975823</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMC Med. 2013;11:159</RefSource><PMID Version="1">23826681</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ophthalmologica. 2013;230(3):144-50</RefSource><PMID Version="1">23989133</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2014;9(7):e102309</RefSource><PMID Version="1">25029255</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA Ophthalmol. 2014 Sep;132(9):1113-22</RefSource><PMID Version="1">25058482</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Adv Ther. 2014 Nov;31(11):1134-54</RefSource><PMID Version="1">25414048</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ophthalmology. 2014 Nov;121(11):2247-54</RefSource><PMID Version="1">25012934</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Ophthalmol. 2015 Jan;159(1):85-91.e1-3</RefSource><PMID Version="1">25261844</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2015 Mar 26;372(13):1193-203</RefSource><PMID Version="1">25692915</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Can J Ophthalmol. 2015 Jun;50(3):209-16</RefSource><PMID Version="1">26040221</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Diabetes Care. 2003 Sep;26(9):2653-64</RefSource><PMID Version="1">12941734</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Epidemiol. 1997 Jun;50(6):683-91</RefSource><PMID Version="1">9250266</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Graefes Arch Clin Exp Ophthalmol. 2009 Feb;247(2):267-72</RefSource><PMID Version="1">18925408</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Health Qual Life Outcomes. 2008;6:95</RefSource><PMID Version="1">18992161</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2010 Jul 10;376(9735):124-36</RefSource><PMID Version="1">20580421</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ophthalmology. 2011 Apr;118(4):615-25</RefSource><PMID Version="1">21459215</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Ophthalmol. 2012 Sep;130(9):1153-61</RefSource><PMID Version="1">22965591</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020533" MajorTopicYN="N">Angiogenesis Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003930" MajorTopicYN="Y">Diabetic Retinopathy</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058449" MajorTopicYN="N">Intravitreal Injections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053685" MajorTopicYN="N">Laser Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008269" MajorTopicYN="Y">Macular Edema</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015233" MajorTopicYN="N">Models, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D063868" MajorTopicYN="N">Patient Outcome Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018579" MajorTopicYN="N">Patient Selection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069579" MajorTopicYN="N">Ranibizumab</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040262" MajorTopicYN="N">Receptors, Vascular Endothelial Growth Factor</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042461" MajorTopicYN="N">Vascular Endothelial Growth Factor A</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014786" MajorTopicYN="Y">Vision Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014792" MajorTopicYN="N">Visual Acuity</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC4846684</OtherID><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Aflibercept</Keyword><Keyword MajorTopicYN="N">Diabetic macular edema</Keyword><Keyword MajorTopicYN="N">Ophthalmology</Keyword><Keyword MajorTopicYN="N">Ranibizumab</Keyword><Keyword MajorTopicYN="N">Vascular endothelial growth factor</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>12</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26951552</ArticleId><ArticleId IdType="doi">10.1007/s12325-016-0310-0</ArticleId><ArticleId IdType="pii">10.1007/s12325-016-0310-0</ArticleId><ArticleId IdType="pmc">PMC4846684</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F72 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001F72 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:26951552
|texte= Using Patient-Level Data to Develop Meaningful Cross-Trial Comparisons of Visual Impairment in Individuals with Diabetic Macular Edema.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:26951552" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |